|
2025
|
G/S
|
Pharmaceutical preparations for the treatment and prevention of oncological, hematological, metab... |
|
|
G/S
|
Pharmaceutical and biological preparations for human use. |
|
|
G/S
|
Pharmaceutical and biological preparations for human use. |
|
2024
|
Invention
|
Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-mor... |
|
|
Invention
|
Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin... |
|
|
Invention
|
Methods for treating systemic lupus erythematosus and the use of biomarkers as a predictor of cli... |
|
|
Invention
|
Salts and solid forms of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidi... |
|
|
Invention
|
Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use.
Provi... |
|
|
Invention
|
Tablet compositions.
Provided herein is a tablet comprising 2-methyl-1-[(4-[6-(trifluoromethyl)p... |
|
|
Invention
|
Heteroaryl compounds as ligand directed degraders of irak4. Provided herein are compounds and com... |
|
|
Invention
|
Transgenic mouse expressing human cereblon.
Provided are transgenic mice whose genome comprises ... |
|
|
Invention
|
Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatmen... |
|
|
Invention
|
Assessment of bcma in biological samples. Provided herein are methods for detection of soluble B-... |
|
|
Invention
|
Compounds and compositions for selective degradation of engineered proteins.
Provided herein are... |
|
|
Invention
|
Compounds and compositions for selective degradation of engineered proteins. Provided herein are ... |
|
|
Invention
|
Compounds and compositions useful as degraders of mk2 kinase. The present disclosure provides com... |
|
|
Invention
|
Processes for the preparation of (s)-tert-butyl 4,5-diamino-5-oxopentanoate.
Provided are proces... |
|
|
Invention
|
Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamm... |
|
|
Invention
|
Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases. ... |
|
|
Invention
|
Antiproliferative compounds and methods of use thereof.
Provided herein is 4-(4-(4-(((2-(2,6-dio... |
|
2023
|
Invention
|
Substituted imidazo-based compounds as ligand directed degraders of irak3. Provided herein are co... |
|
|
Invention
|
Heterocyclic compounds as modulators of s1p5. Provided herein are compounds and compositions ther... |
|
|
Invention
|
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and met... |
|
|
Invention
|
Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodie... |
|
|
Invention
|
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy. Provided... |
|
|
Invention
|
Mk2 inhibitors and uses thereof.
The present invention provides compounds, compositions thereof,... |
|
|
Invention
|
Mk2 inhibitors and uses thereof. The present invention provides compounds, compositions thereof, ... |
|
|
Invention
|
Crystalline forms of 3-({[(4r)-7-{methyl[4-(propan-2-yl)phenyl]amino}-3,4-dihydro-2h-1-benzopyran... |
|
|
Invention
|
Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2... |
|
|
Invention
|
Methods for treating multiple myeloma. Provided herein are methods of treating multiple myeloma, ... |
|
|
Invention
|
Heteroaryl compounds as ligand directed degraders of irak4.
Provided herein are compounds and co... |
|
|
Invention
|
Methods and compositions for reduction of immunogenicity.
Provided herein are methods and uses i... |
|
|
Invention
|
3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatme... |
|
2022
|
Invention
|
Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases.
Pr... |
|
|
Invention
|
Cereblon binding compounds, compositions thereof, and methods of treatment therewith.
Provided h... |
|
|
Invention
|
Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoaze... |
|
|
Invention
|
Methods of treating multiple myeloma using combination therapy.
Provided herein are methods of u... |
|
|
Invention
|
Pkc-theta modulators.
Disclosed are compounds, compositions and methods for treating disease, sy... |
|
|
Invention
|
Methods of treating b-cell lymphoma using combination therapy.
Provided herein are methods of us... |
|
|
Invention
|
Combination therapies with bcma-directed t cell therapy.
Provided herein are methods, compositio... |
|
|
Invention
|
Treatment of cancer with kdm4 inhibitors.
Provided herein are compositions and methods for the t... |
|
|
Invention
|
Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation ... |
|
|
Invention
|
Methods for treating multiple myeloma.
Provided herein are methods of treating multiple myeloma,... |
|
|
Invention
|
Sulfonamides and their use for treatment of helminthic infections and diseases.
Provided herein ... |
|
2021
|
Invention
|
Heterocyclic compounds and their use for parasitic diseases.
Provided herein are compounds of Fo... |
|
|
Invention
|
Actriib ligand trap compositions and uses thereof. The present application relates to recombinant... |
